DiabetOmics
Modality Dx is an innovator in rapid test technologies for risk assessment and diagnosis in maternal health, diabetes, and autoimmune disease. They focus on developing molecular Signatures to support patient care, disease prediction, and early intervention. The company leverages advanced data science, molecular innovation, and patented science to redefine disease detection, understanding, and treatment, aiming to improve healthcare outcomes and support pharmaceutical development.
Industries
Nr. of Employees
small (1-50)
DiabetOmics
2345 NE Overlook Drive, Suite #140, Hillsboro, OR 97006
Patents
Salivary protein glycosylation test for diagnosis and monitoring of diabetes
US-9383352-B2
View DetailsMethods for detecting pre-diabetes and diabetes using differential protein glycosylation
US-8530175-B2
View Details
Salivary protein glycosylation test for diagnosis and monitoring of diabetes
US-9383352-B2
View DetailsMethods for detecting pre-diabetes and diabetes using differential protein glycosylation
US-8530175-B2
View DetailsProducts
Point-of-care preeclampsia biomarker test (glycosylated fibronectin)
A rapid point-of-care assay measuring glycosylated fibronectin intended for assessment and short-term prediction of preeclampsia in pregnant patients.
Point-of-care C‑peptide test
Rapid point-of-care assay for quantitative estimation of C‑peptide to support diabetes care and classification.
Point-of-care autoantibody panel for diabetes-related autoantibodies
Rapid POC tests targeting diabetes-associated autoantibodies (including GAD, IA-2 and insulin autoantibodies) intended for detection of adaptive immune response markers.
Oral fluid SARS‑CoV‑2 antibody test (EUA-authorized use)
An oral fluid antibody assay authorized for emergency use to qualitatively detect total SARS‑CoV‑2 antibodies in gingival crevicular fluid for identifying adaptive immune response.
Point-of-care preeclampsia biomarker test (glycosylated fibronectin)
A rapid point-of-care assay measuring glycosylated fibronectin intended for assessment and short-term prediction of preeclampsia in pregnant patients.
Point-of-care C‑peptide test
Rapid point-of-care assay for quantitative estimation of C‑peptide to support diabetes care and classification.
Point-of-care autoantibody panel for diabetes-related autoantibodies
Rapid POC tests targeting diabetes-associated autoantibodies (including GAD, IA-2 and insulin autoantibodies) intended for detection of adaptive immune response markers.
Oral fluid SARS‑CoV‑2 antibody test (EUA-authorized use)
An oral fluid antibody assay authorized for emergency use to qualitatively detect total SARS‑CoV‑2 antibodies in gingival crevicular fluid for identifying adaptive immune response.
Services
Collaborative development of condition-specific biomarker signatures using proteomic data and AI to deliver a validated diagnostic panel within accelerated timelines.
Use of molecular signatures and biomarker assays to support patient stratification, endpoint measurement, and assessment of therapeutic response for pharmaceutical programs.
Partnerships to develop non-invasive saliva-based tests for disease risk screening and antibody detection across multiple disease indications.
Collaborative development of condition-specific biomarker signatures using proteomic data and AI to deliver a validated diagnostic panel within accelerated timelines.
Use of molecular signatures and biomarker assays to support patient stratification, endpoint measurement, and assessment of therapeutic response for pharmaceutical programs.
Partnerships to develop non-invasive saliva-based tests for disease risk screening and antibody detection across multiple disease indications.
Expertise Areas
- Biomarker discovery and signature development
- Point-of-care diagnostic development
- Oral fluid (saliva) diagnostics
- Proteomics and glycosylation analysis
Key Technologies
- Molecular signature biomarker panels
- Oral fluid (saliva) sampling
- Point-of-care quantitative immunoassays
- Proteomics
News & Updates
Diabetomics has been rebranded as Modality Dx, focusing on rapid test technologies for risk assessment and diagnosis in maternal health, diabetes, and autoimmune diseases.
Partnership to develop rapid tests for Type 1 diabetes screening.
Publication of clinical studies on glycosylated fibronectin for preeclampsia risk assessment.
Presentation of clinical studies on preeclampsia at a major conference.
Development of a rapid test for autoimmune biomarker anti-citrullinated albumin (ACA).
CE marking obtained for several autoantibody tests.
Diabetomics has been rebranded as Modality Dx, focusing on rapid test technologies for risk assessment and diagnosis in maternal health, diabetes, and autoimmune diseases.
Partnership to develop rapid tests for Type 1 diabetes screening.
Publication of clinical studies on glycosylated fibronectin for preeclampsia risk assessment.
Presentation of clinical studies on preeclampsia at a major conference.
Development of a rapid test for autoimmune biomarker anti-citrullinated albumin (ACA).
CE marking obtained for several autoantibody tests.